Mycenax Biotech Total Liabilities
Mycenax Biotech total liabilities. Based on the latest financial reports, Mycenax Biotech (4726) has total liabilities worth NT$1.69 Billion TWD (≈ $53.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Mycenax Biotech liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mycenax Biotech (2017–2024)
Total liabilities of Mycenax Biotech from 2017 to 2024. This chart illustrates how Mycenax Biotech's total liabilities have evolved over time, based on quarterly financial data.
Mycenax Biotech Competitors by Total Liabilities
The table below lists competitors of Mycenax Biotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bionime Corp
TW:4737
|
Taiwan | NT$3.44 Billion |
|
Dazhong Transportation Group Co Ltd B
SHG:900903
|
China | $8.41 Billion |
|
DUG Technology Ltd
AU:DUG
|
Australia | AU$44.17 Million |
|
Masterflex SE
F:MZX
|
Germany | €30.41 Million |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
Malaysia | RM21.65 Million |
|
Bisalloy Steel Group Ltd
AU:BIS
|
Australia | AU$40.84 Million |
|
Traeger Inc
NYSE:COOK
|
USA | $486.85 Million |
|
Kelly Partners Group Holdings Ltd
AU:KPG
|
Australia | AU$161.97 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Mycenax Biotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Mycenax Biotech (4726) total assets.
Liquidity & Leverage Metrics
Mycenax Biotech Total Liabilities Ratios Explained
Mycenax Biotech total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mycenax Biotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mycenax Biotech (2017–2024)
The table below shows the annual total liabilities of Mycenax Biotech from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.34 Billion ≈ $42.37 Million |
+1.64% |
| 2023-12-31 | NT$1.32 Billion ≈ $41.69 Million |
-1.80% |
| 2022-12-31 | NT$1.35 Billion ≈ $42.45 Million |
+9.34% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.83 Million |
+127.84% |
| 2020-12-31 | NT$540.89 Million ≈ $17.04 Million |
+76.74% |
| 2019-12-31 | NT$306.04 Million ≈ $9.64 Million |
+44.56% |
| 2018-12-31 | NT$211.70 Million ≈ $6.67 Million |
+25.32% |
| 2017-12-31 | NT$168.93 Million ≈ $5.32 Million |
-- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more